Investigation into Capricor Therapeutics
In recent developments, Robbins LLP has alerted investors regarding a class action lawsuit filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR). This investigation concerns investors who purchased or acquired Capricor's securities between October 9, 2024, and July 10, 2025.
About Capricor Therapeutics
Capricor Therapeutics is a clinical-stage biotechnology company focused on developing cutting-edge cell and exosome-based therapeutics. Their leading product candidate, deramiocel, aims to treat Duchenne muscular dystrophy (DMD) and other critical conditions that lack effective therapies. This innovative approach highlights Capricor's commitment to advancing treatment options for patients with unmet medical needs.
Why the Lawsuit?
Recent allegations state that during the investigation period, Capricor misled investors about the efficacy and safety of their drug candidate deramiocel. According to court documents, the company projected confidence in receiving the first approval for DMD cardiomyopathy treatment while hiding critical adverse data regarding the long-term effects of the drug.
Material Facts Concealed
The complaint reveals that essential details from a four-year safety and efficacy study conducted during the Phase 2 HOPE-2 trial were not disclosed by the company. This lack of transparency led to investors purchasing shares at inflated prices, under the impression that the drug was closer to FDA approval than it actually was.
Impact of Recent Regulatory Decisions
An important turning point occurred on July 11, 2025, when Capricor announced that they received a Complete Response Letter (CRL) from the FDA. The CRL stated that the company failed to meet the statutory requirements for demonstrating the effectiveness of deramiocel. Moreover, the need for additional clinical data suggested that the company was not forthcoming about the product’s challenges.
Stock Price Repercussions
This announcement had immediate consequences on the stock market, leading to a drop in Capricor's stock from $11.40 per share the previous day to $7.64 on the day following the release. Such rapid price fluctuations often alert investors to deeper issues within a company and raise questions about its governance practices.
Next Steps for Investors
Currently, shareholders of Capricor Therapeutics may be eligible to participate in the class action lawsuit. Individuals interested in taking a leading role in this litigation should contact Robbins LLP. Serving as the lead plaintiff entails representing other class members in directing the litigation process, but participation is not required to recover any losses.
How to Join the Class Action
If you believe you were affected by the actions of Capricor Therapeutics or have questions regarding the potential for involvement in the class action, you can connect with Robbins LLP by filling out an online form or contacting attorney Aaron Dumas, Jr. directly via email or phone for further guidance.
Summary and Contact Information
Robbins LLP has established a reputation for representing shareholders in corporate legal matters since 2002. Their commitment to protecting investor rights through effective litigation is evident in their proactive stance against management malpractice.
For those wanting notifications regarding the progress of the class action against Capricor Therapeutics, interested parties can sign up for alerts directly on the Robbins LLP website. Engaging with legal experts ensures shareholders stay informed about crucial developments in their investments.
Contact:
Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
(800) 350-6003
adumas@robbinsllp.com
www.robbinsllp.com
Frequently Asked Questions
What is the class action against Capricor Therapeutics about?
The class action relates to allegations that Capricor misled investors regarding the effectiveness and safety of its drug candidate deramiocel.
Who is eligible to join the class action?
Investors who purchased Capricor's securities between October 9, 2024, and July 10, 2025, may be eligible to participate.
How can I participate in the lawsuit?
Interested investors should contact Robbins LLP to discuss their potential participation and understand the leadership role in the class action.
What were the results of the FDA’s response regarding deramiocel?
Capricor received a Complete Response Letter indicating that the drug did not meet necessary efficacy requirements and additional clinical data is required.
What happens if I don’t participate in the class action?
Shareholders can choose not to participate and still remain an absent class member, which allows them inclusion in any potential recovery.
